Featured Stock to Focus: Glaxosmithkline Plc (NYSE:GSK)

Lloyd Doyle
December 7, 2017

GlaxoSmithKline plc (NYSE:GSK) attracted analysts when it go through a change of -0.40% to trade at $34.86. The institutional investor owned 71,794 shares of the pharmaceutical company's stock after acquiring an additional 9,002 shares during the period. Pegasus Partners Ltd.'s holdings in GlaxoSmithKline were worth $1,951,000 as of its most recent SEC filing. Hotchkis & Wiley Capital Management LLC grew its holdings in GlaxoSmithKline by 4.3% in the second quarter. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.62. FMR LLC raised its position in GlaxoSmithKline by 5.9% in the second quarter. The business had revenue of GBX 784.30 billion during the quarter. Also, insider Simon Dingemans purchased 1,076 shares of the firm's stock in a transaction dated Thursday, October 12th. Renaissance Technologies LLC grew its holdings in GlaxoSmithKline by 112.1% in the second quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company's stock valued at $164,000 after buying an additional 1,955 shares in the last quarter.

Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.

GlaxoSmithKline plc (GSK) has shown a downward trend during time of recent session. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company's stock worth $4,054,000 after buying an additional 10,017 shares during the last quarter. The Stock has its 52-week High of $44.53 and 52-Week Low of $34.72 and it touched its 52-week high on 05/31/17 and 52-Week Low on 11/15/17.

Liquidity ratios help investors to determine a company's ability to pay off its debts. Shareholders of record on Thursday, November 9th will be paid a dividend of GBX 19 ($0.26) per share. This is an increase from GlaxoSmithKline's previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a yield of 5.81%. GlaxoSmithKline's dividend payout ratio is now 163.12%.

In other GlaxoSmithKline news, insider Urs Rohner bought 473 shares of the company's stock in a transaction dated Wednesday, October 25th. The stock was bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter. Finally, TheStreet upgraded shares of GlaxoSmithKline plc from a "c" rating to a "b" rating in a research report on Friday, May 19th. Finally, Argus decreased their price target on GlaxoSmithKline to $40.00 and set a "buy" rating on the stock in a research note on Thursday, November 30th. BNP Paribas raised GlaxoSmithKline plc from an "underperform" rating to a "neutral" rating and reduced their price objective for the stock from $45.58 to $37.20 in a report on Wednesday, April 5th. The company presently has a consensus rating of "Hold" and a consensus price target of GBX 1,577.14 ($21.23). Investec downgraded GlaxoSmithKline to a "hold" rating and dropped their price target for the stock from GBX 1,800 ($24.23) to GBX 1,390 ($18.71) in a research report on Monday, November 6th.

Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Glaxosmithkline Plc (NYSE:GSK) as Buy, 1 analysts given Outperform signal, 1 reported Hold, and 0 analysts rated the stock as Sell. The company has a consensus rating of "Buy" and a consensus price target of $45.25.

Other reports by Iphone Fresh

Discuss This Article